Pharmacological mechanism of roflumilast in the treatment of asthma–COPD overlap

References

• McnaughtonAWeatherallMWilliamsMSing Your Lungs Out-a community singing group for chronic obstructive pulmonary disease: a 1-year pilot studyBMJ Open201771e014151
   Web of Science ®Google Scholar
• global Initiative for Asthma [homepage on the Internet]Global Strategy for Asthma Management and Prevention2017 Available from: www.ginasthma.org
   Google Scholar
• de MarcoRPesceGMarconAThe coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general populationPLoS One201385e6298523675448
   PubMed Web of Science ®Google Scholar
• KangJYaoWCaiBChenPLingXShangHCurrent situation of asthma-COPD overlap syndrome (ACOS) in Chinese patients older than 40 years with airflow limitation: rationale and design for a multi-center, cross-sectional trial (study protocolJ Thorac Dis20168123744375128149573
   PubMed Web of Science ®Google Scholar
• WurstKEKelly-ReifKBushnellGAPascoeSBarnesNUnderstanding asthma-chronic obstructive pulmonary disease overlap syndromeRespir Med201611011126525374
   PubMed Web of Science ®Google Scholar
• TurnerAMTamasiLSchleichFClinically relevant subgroups in COPD and asthmaEur Respir Rev20152413628329826028640
   PubMedGoogle Scholar
• BarrechegurenMEsquinasCMiravitllesMThe asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): opportunities and challengesCurr Opin Pulm Med2015211747925405671
   PubMed Web of Science ®Google Scholar
• GibsonPGSimpsonJLThe overlap syndrome of asthma and COPD: what are its features and how important is it?Thorax200964872873519638566
   PubMed Web of Science ®Google Scholar
• GauvreauGMBouletLPSchmid-WirlitschCRoflumilast attenuates allergen-induced inflammation in mild asthmatic subjectsRespir Res20111214022029856
   PubMed Web of Science ®Google Scholar
• LouieSZekiAASchivoMThe asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerationsExpert Rev Clin Pharmacol20136219721923473596
   PubMed Web of Science ®Google Scholar
• HardinMSilvermanEKBarrRGCOPD Gene InvestigatorsThe clinical features of the overlap between COPD and asthmaRespir Res20111212721951550
   PubMed Web of Science ®Google Scholar
• PadrãoEAraújoDTodo BomABomATAsthma-COPD overlap: a Portuguese surveyPulmonology2018
   Web of Science ®Google Scholar
• LeeHYKangJYYoonHKClinical characteristics of asthma combined with COPD featureYonsei Med J201455498098624954327
   PubMed Web of Science ®Google Scholar
• PerezDLLCosíoBGMiravitllesMPlaza VCHACOS Study GroupAccuracy of a new algorithm to identify asthma–COPD overlap (ACO) patients in a cohort of patients with chronic obstructive airway diseaseArch Bronconeumol201854419820429229474
   PubMed Web of Science ®Google Scholar
• McdonaldVMSimpsonJLHigginsIGibsonPGMultidimensional assessment of older people with asthma and COPD: clinical management and health statusAge Ageing2011401424921087988
   PubMed Web of Science ®Google Scholar
• BarnesNCThe properties of inhaled corticosteroids: similarities and differencesPrim Care Respir J200716314915417530144
   PubMedGoogle Scholar
• HouGKangJMore attention to comprehensive assessment and individualized therapy of chronic obstructive pulmonary diseaseJ Transl Int Med201532394227847885
   PubMedGoogle Scholar
• MokryJUrbanovaAMedvedovaIEffects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyper-responsiveness in guinea pigsJ Physiol Pharmacol201768572173029375047
   PubMed Web of Science ®Google Scholar
• MeltzerEOChervinskyPBusseWRoflumilast for asthma: Efficacy findings in placebo-controlled studiesPulm Pharmacol Ther201535SupplS20S2726498386
   PubMed Web of Science ®Google Scholar
• BarnetteMSPhosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)Prog Drug Res19995319322910616299
   PubMedGoogle Scholar
• InagakiNMiuraTDaikokuMNagaiHKodaAInhibitory effects of beta-adrenergic stimulants on increased vascular permeability caused by passive cutaneous anaphylaxis, allergic mediators, and mediator releasers in ratsPharmacology198939119272479953
   PubMed Web of Science ®Google Scholar
• ManningCDBurmanMChristensenSBSuppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4BBr J Pharmacol199912871393139810602317
   PubMed Web of Science ®Google Scholar
• FerreiraJDrummondMPiresNGI DPOC-Grupo de Inter-esse na Doença Pulmonar Obstrutiva CrónicaOptimal treatment sequence in COPD: Can a consensus be found?Rev Port Pneumol2016221394926655798
   PubMed Web of Science ®Google Scholar
• BardinPKanniessFGauvreauGBredenbrökerDRabeKFRoflumilast for asthma: Efficacy findings in mechanism of action studiesPulm Pharmacol Ther201535SupplS4S1026296794
   PubMed Web of Science ®Google Scholar
• BatemanEDBousquetJAubierMBredenbrökerDO’ByrnePMRoflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studiesPulm Pharmacol Ther201535SupplS11S1926456372
   PubMed Web of Science ®Google Scholar
• RennardSICalverleyPMGoehringUMBredenbrökerDMartinezFJReduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPDRespir Res2011121821272339
   PubMed Web of Science ®Google Scholar
• LuoPLiSChenYEfficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysisJ Thorac Dis2016892638264527747018
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMAAlbertRKPrevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guidelineEur Respir J2017503160226528889106
   PubMed Web of Science ®Google Scholar
• HananiaNACalverleyPMDransfieldMTPooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPDRespir Med2014108236637524120253
   PubMed Web of Science ®Google Scholar
• ChongJPoolePLeungBBlackPNPhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20115CD002309
   Google Scholar
• KankaanrantaHHarjuTKilpeläinenMDiagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelinesBasic Clin Pharmacol Toxicol2015116429130725515181
   PubMed Web of Science ®Google Scholar
• YanJHGuWJPanLEfficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysisPulm Pharmacol Ther2014271838923624309
   PubMed Web of Science ®Google Scholar
• BredenbrokerDSyedJLeichtlSRathgebFWurstWRoflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary diseaseEur Respir J200220suppl 38374S abstr
   Google Scholar
• RabeKFChapmanKRJubertJVetterNWitteSBredenbroekerDRoflumilast, a novel selective phosphodiesterase 4 inhibitor improves lung function in patients with moderate to severe COPDAm J Respir Crit Care Med2004169A518
   Google Scholar
• LipworthBJPhosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary diseaseLancet2005365945416717515639300
   PubMed Web of Science ®Google Scholar
• HatzelmannAMorcilloEJLungarellaGThe preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulm Pharmacol Ther201023423525620381629
   PubMed Web of Science ®Google Scholar
• PanLGuoYZZhangBYanJHDoes roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysisJ Thorac Dis20135442242923991297
   PubMed Web of Science ®Google Scholar
• LouwCWilliamsZVenterLRoflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challengeRespiration200774441141716954654
   PubMed Web of Science ®Google Scholar
• HerbertCHettiaratchiAWebbDCThomasPSFosterPSKumarRKSuppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthmaClin Exp Allergy200838584785618307529
   PubMed Web of Science ®Google Scholar
• TimmerWLeclercVBirrauxGThe new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthmaand leads to suppression of LPS-stimulated TNF-alpha ex vivoJ Clin Pharmacol200242329730311865966
   PubMed Web of Science ®Google Scholar
• van SchalkwykEMvan HeerdenKBredenbrokerDDose-dependent inhibitory effect of roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reactionEur Respir J200220suppl 38110S
   Google Scholar
• LeichtlSSchmid-WirlitschCBredenbrökerDRathgebFWurstWRoflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthmaEur Respir J200220suppl 38303S abstr
   Google Scholar
• ShantakumarSPwuRFD’SilvaLBurden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based studyBMC Pulm Med20181811629368608
   PubMed Web of Science ®Google Scholar
• D’SilvaLHassanNWangHYHeterogeneity of bronchitis in airway diseases in tertiary care clinical practiceCan Respir J201118314414821766077
   PubMed Web of Science ®Google Scholar
• PapaiwannouAZarogoulidisPPorpodisKAsthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature reviewJ Thorac Dis20146Suppl 1S146S15124672688
   PubMed Web of Science ®Google Scholar
• MendesESRebolledoPCadetLAranaJScmidAWannerAEffect of roflumilast on airway blood flow in COPD: a pilot studyChronic Obstr Pulm Dis20174426226429354670
   PubMed Web of Science ®Google Scholar
• MuradHAHabibHSRafeeqMMSulaimanMIAbdulrahmanASKhabazMNCo-inhalation of roflumilast, rather than formoterol, with fluticasone more effectively improves asthma in asthmatic miceExp Biol Med20172425516526
   Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• YalcinADCelikBYalcinANOmalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levelsImmunopharmacol Immunotoxicol201638325325627121601
   PubMed Web of Science ®Google Scholar
• AraújoDPadrãoEMorais-AlmeidaMAsthma-chronic obstructive pulmonary disease overlap syndrome – literature review and contributions towards a Portuguese consensusRev Port Pneumol2017232909928089081
   PubMed Web of Science ®Google Scholar
• KawamatawongTRoles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseasesJ Thorac Dis2017941144115428523172
   PubMed Web of Science ®Google Scholar
• BatemanESinghDSmithDEfficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesInt J Chron Obstruct Pulmon Dis2010519720820714373
   PubMedGoogle Scholar
• MarshSETraversJWeatherallMProportional classifications of COPD phenotypesThorax200863976176718728201
   PubMed Web of Science ®Google Scholar
• KimSWKimJHParkCKEffect of roflumilast on airway remodelling in a murine model of chronic asthmaClin Exp Allergy201646575476326542330
   PubMed Web of Science ®Google Scholar
• BarnesNCSaettaMRabeKFImplementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilastBMC Pulm Med201414924484726
   PubMed Web of Science ®Google Scholar
• JianliPLunHLingOClinical values of interleukin-17 in the differentiation of asthma, chronic obstructive pulmonary disease and asthma chronic obstructive pulmonary disease overlap syndromeChin J Lung Dis(Electronic Edition)201659479483 Chinese
   Google Scholar